HomeCompareCMVLF vs XYLD

CMVLF vs XYLD: Dividend Comparison 2026

CMVLF yields 64.94% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMVLF wins by $802.2K in total portfolio value
10 years
CMVLF
CMVLF
● Live price
64.94%
Share price
$3.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$827.5K
Annual income
$205,354.23
Full CMVLF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — CMVLF vs XYLD

📍 CMVLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMVLFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMVLF + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMVLF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMVLF
Annual income on $10K today (after 15% tax)
$5,519.48/yr
After 10yr DRIP, annual income (after tax)
$174,551.10/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, CMVLF beats the other by $171,814.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMVLF + XYLD for your $10,000?

CMVLF: 50%XYLD: 50%
100% XYLD50/50100% CMVLF
Portfolio after 10yr
$426.4K
Annual income
$104,286.63/yr
Blended yield
24.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CMVLF right now

CMVLF
Analyst Ratings
7
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
-0.9
Piotroski
2/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMVLF buys
0
XYLD buys
0
No recent congressional trades found for CMVLF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMVLFXYLD
Forward yield64.94%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$827.5K$25.3K
Annual income after 10y$205,354.23$3,219.02
Total dividends collected$696.1K$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CMVLF vs XYLD ($10,000, DRIP)

YearCMVLF PortfolioCMVLF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$17,194$6,493.51$10,818$1,098.39+$6.4KCMVLF
2$28,831$10,434.22$11,738$1,222.51+$17.1KCMVLF
3$47,202$16,352.17$12,774$1,364.64+$34.4KCMVLF
4$75,526$25,019.87$13,944$1,527.86+$61.6KCMVLF
5$118,227$37,414.37$15,270$1,715.87+$103.0KCMVLF
6$181,239$54,736.40$16,775$1,933.09+$164.5KCMVLF
7$272,346$78,420.28$18,490$2,184.87+$253.9KCMVLF
8$401,542$110,132.11$20,450$2,477.63+$381.1KCMVLF
9$581,404$151,754.11$22,697$2,819.19+$558.7KCMVLF
10$827,457$205,354.23$25,280$3,219.02+$802.2KCMVLF

CMVLF vs XYLD: Complete Analysis 2026

CMVLFStock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Full CMVLF Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this CMVLF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMVLF vs SCHDCMVLF vs JEPICMVLF vs OCMVLF vs KOCMVLF vs MAINCMVLF vs QYLDCMVLF vs JEPQCMVLF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.